Suppr超能文献

慢性淋巴细胞白血病中的霍奇金淋巴瘤转化为里希特转化型:世界文献回顾性分析。

Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature.

机构信息

Department of Internal Medicine, University of Connecticut Medical Center, Farmington, CT 06030-1235, USA.

出版信息

Br J Haematol. 2012 Jan;156(1):50-66. doi: 10.1111/j.1365-2141.2011.08907.x. Epub 2011 Oct 24.

Abstract

Richter transformation in chronic lymphocytic leukaemia (CLL) represents an entity of considerable genetic, molecular, immunological and clinical heterogeneity. A rare occurrence, Hodgkin variant of Richter syndrome, has not been comprehensively characterized or systematized to date. We conducted a retrospective analysis of the existing cases of Hodgkin lymphoma as Richter syndrome reported in the medical literature in the previous three and a half decades. Our search identified 86 such patients; this entity affects predominantly older men and the most common histological subtype is mixed cellularity. Interval between the diagnosis of CLL and subsequent development of Hodgkin lymphoma is circa 4.3 years. The overall survival of patients was approximately 1.7 years in our analysed cohort. However, our pooled data showed that patients in whom CLL had been treated with fludarabine had a shorter survival after transformation compared to the ones not treated with this agent. The role of immunosuppression and Epstein-Barr virus infection in the aetiopathogenesis of this entity remains to be clarified.

摘要

慢性淋巴细胞白血病(CLL)中的里希特转化是一种具有显著遗传、分子、免疫和临床异质性的疾病。霍奇金淋巴瘤变异型里希特综合征较为罕见,目前尚未得到全面的描述和分类。我们对过去三十五年间医学文献中报道的 CLL 作为里希特综合征的霍奇金淋巴瘤病例进行了回顾性分析。我们的检索共确定了 86 例此类患者;该疾病主要影响老年男性,最常见的组织学亚型为混合细胞型。CLL 诊断与随后发生霍奇金淋巴瘤之间的间隔约为 4.3 年。在我们分析的队列中,患者的总生存率约为 1.7 年。然而,我们的汇总数据显示,与未接受该药物治疗的患者相比,接受氟达拉滨治疗的 CLL 患者在转化后生存时间更短。免疫抑制和 Epstein-Barr 病毒感染在该疾病发病机制中的作用仍有待阐明。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验